Project Grant HT94252310472
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$1.7M
Federal Agency
Defense Health Agency
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Hamden, CT 06511, USA
Similar Awards
The Defense Health Agency awarded Yale University a $3,129,087.00 Project Grant on September 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant supports advanced research to develop integrative platforms for cellular immunotherapies against resistant hematopoietic malignancies and solid tumors. Key aims include targeting combinations of gene editing and CAT inhibition to enhance CAR-T cell function, and investigating gene editing coupled with CAT...
The Defense Health Agency awarded Yale University a 3-year, USD 1,277,053 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to target the chromatin regulator WDR5 to treat breast cancer metastasis. The project aims to advance the understanding and development of novel therapeutic approaches for breast cancer, a leading cause of cancer-related deaths. As the prime awardee, Yale University will conduct the research, development, and testing activities...
The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...
The U.S. Department of Defense's Defense Health Agency awarded a $1,235,447 Project Grant to Yale University on July 1, 2023. This 3-year grant, funded under the Military Medical Research and Development program (CFDA 12.420), will support research targeting the chromatin regulator WDR5 to treat breast cancer metastasis. The project aims to transform health care for service members and the general public through innovative and impactful biomedical research investigating medical solutions for...
The Yale University was awarded a $753,749 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from March 2022 through March 2025 to target replication stress in triple-negative breast cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical...
This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing...
The Defense Health Agency awarded Yale University a $837,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "MECHANISM-CENTRIC PREDICTIVE MODELING FOR PROSTATE CANCER". The 3-year grant, running from July 1, 2024 to June 30, 2027, supports Yale's work to develop new predictive modeling approaches for prostate cancer. This research aims to improve understanding of the underlying biological mechanisms driving prostate...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,130,469 to Yale University to uncover the tumor-immune microenvironmental determinants of immunotherapy response in renal cell carcinoma through ex vivo patient-derived models. The research aims to transform health care for Service Members and the American public through innovative and impactful research investigating medical solutions for the...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,158,989.00 to Yale University to conduct research on optimizing adoptive cellular immunotherapy for rare melanomas. The research project commenced on September 1, 2023 and is scheduled for completion by August 31, 2026. The key objectives of this grant-funded research are to advance innovative medical solutions for rare forms of melanoma that are difficult to...